Rebranding of horse racing is bearing fruit
The transformation is bearing fruit. Among the 1.7 million who attended last season were nearly 200,000 mainland tourists, more than double the number for the previous season.
The Hong Kong Jockey Club has responded well to the call by Chief Executive John Lee Ka-chiu for horse racing to be one of the unique Hong Kong experiences appealing to visitors. Race days now feature live music, DJs and a focus on food and drink. The aim is to offer a 'cool' experience to complement the sporting action. This is drawing a new generation of young fans. Some of them, encouragingly, don't even bet.
The club, which has a monopoly on legal gambling in Hong Kong and pumps billions into charitable causes, is establishing itself as a global sports and entertainment brand. It has teamed up with American Idol creator Simon Fuller. One of his bands is to play at the races.
Racing, though, remains at the heart of the events. Hong Kong hailed three champion horses – Ka Ying Rising, Romantic Warrior and Voyage Bubble – last season. The introduction of lawful gambling on basketball will boost the club's revenue as well as the government's coffers and is intended to draw money away from illicit bookmakers. The club's Conghua racecourse in Guangzhou, meanwhile, provided more winners than before and will start staging races next year.
Amid all the excitement, the risk of gambling leading to addiction, with serious social consequences, must not be forgotten. More must be done to prevent problem gambling and to help addicts. Horse racing has long been an iconic Hong Kong event which has flourished under the 'one country, two systems' concept. China's former paramount leader Deng Xiaoping famously said horse racing would continue after the 1997 handover. As the club adapts to changing times, the sport is set to become an even bigger winner.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
South China Morning Post
28 minutes ago
- South China Morning Post
4 more Hong Kong premium taxi fleets hit the streets after getting full licences
Four more premium taxi service fleets hit the streets on Monday after securing full licences from authorities. Advertisement A Transport Department spokesman said it had granted full taxi fleet licences to four firms, allowing them to operate for five years. 'The four fleets officially commenced services [on Monday],' he said. The four fleets are run by Big Boss Taxi Company, CMG Fleet Management, Sino Development (International) and Tai Wo Management. Sino Development's Big Bee fleet is offering a mixed taxi service, while the other three will only operate urban cabs. Advertisement Earlier this month, SynCab received the same licence to offer premium taxi services in the city.
South China Morning Post
28 minutes ago
- South China Morning Post
McDonald's seeks US$153 million for 8 Hong Kong retail properties in rare asset sale
McDonald's Corp is selling eight retail properties in Hong Kong with an estimated market value of HK$1.2 billion (US$153 million), giving investors a rare opportunity to own fully tenanted assets, as the world's biggest fast-food chain reviews its real estate portfolio in the city. The Chicago-based group appointed JLL as the sole agent to find buyers for its assets in Tsim Sha Tsui, Causeway Bay, Mong Kok, Kennedy Town, Tai Kok Tsui, Yuen Long, Tsuen Wan and Tsz Wan Shan, according to a statement on Monday. The public tender closes on September 16, it added. McDonald's said it would continue to operate its restaurants in the eight locations on long-term leases. Some of the properties would be sold with additional tenancies involving 7-Eleven convenience stores and independent pharmacies, it added. 'This is an exceptional opportunity – one that has not occurred in decades – to acquire high-quality retail assets backed by resilient tenants like McDonald's, who have maintained long-lasting leases and strong cash flow,' said Eunice Tang, executive director of capital markets at JLL in Hong Kong. With a 100 per cent occupancy, the portfolio offers stable income, supported by a high rental yield, the agent said. McDonald's Star House outlet on Salisbury Road in Tsim Sha Tsui. Photo: Handout JLL has 'received significant interest from a wide pool of potential investors', Tang said.
South China Morning Post
an hour ago
- South China Morning Post
GSK signs US$12.5 billion licence deal with Hengrui as China rises in global pharmaceuticals
GlaxoSmithKline (GSK) will pay a Chinese company US$12.5 billion for exclusive global rights to develop a dozen drugs, in a landmark deal that underscores how China's research labs are snapping up market share in the global pharmaceutical and biomedical industries. The deal would give GSK the rights to develop a drug for treating chronic obstructive pulmonary disease (COPD) called HRS-9821, as well as 11 of the preclinical programmes owned by Jiangsu Hengrui Pharmaceuticals. The global rights exclude mainland China, Taiwan, Hong Kong and Macau, according to a statement to the Hong Kong stock exchange on Monday. The deal is the latest in a string of transactions between multinational firms and Chinese drug developers, which have bolstered China's share of global licensing deal value to 28 per cent in 2024 from 1 per cent in 2019. Pfizer agreed in May to pay US$1.25 billion to Shenyang-based 3SBio for the exclusive right to develop the Chinese company's drug for treating solid tumours. China's pharmaceutical out-licensing value soared to almost US$66 billion in the first six months of 2025, more than the whole of last year, according to a July 14 report from China Post Securities. For multinational companies, the deals gave them exclusive products to expand their portfolio and pipelines, while the Chinese developers saw them as opportunities to cash in on prior work and fund new projects. The GSK corporate flag next to a Chinese national flag outside its office building in Shanghai on July 12, 2013. Photo: Reuters Hengrui, established in the Jiangsu provincial city of Lianyungang in 1997, would receive a US$500 million upfront payment and charge US$12 billion to GSK upon the achievement of development, regulatory approval and sales milestones. 'The signing of the agreement will help expand the international market for HRS-9821 and multiple innovative medicines in various therapeutic areas, including oncology, respiratory, immunology and inflammation, providing high-quality treatment options for patients worldwide,' Hengrui said in a statement.
